Accretion Pharmaceuticals Limited (NSE:ACCPL)

Market Cap	711.98M
Revenue (ttm)	826.43M
Net Income (ttm)	90.81M
Shares Out	11.12M
EPS (ttm)	9.82
PE Ratio	6.52
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,000
Average Volume	18,480
Open	66.55
Previous Close	64.10
Day's Range	66.55 - 67.30
52-Week Range	53.80 - 102.50
Beta	n/a
RSI	30.22
Earnings Date	Jan 9, 2026

About Accretion Pharmaceuticals

Accretion Pharmaceuticals Limited engages in the manufacturing and marketing of pharmaceutical products in India. The company offers antibiotic, antibacterial, antifungal, anti-inflammatory, anti-spasmodic, antihistamine, antiallergy, anticough, anticold, antiulcer, gastrointestinal, antacid, anti-diabetic, cardiac, anti-hypertensive, psychotropic, memory enhancer, vitamins, supplements, and other products. It also provides external preparation, oral powder, effervescent formulation, and nutraceutical products, as well as formulations for brain...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 125
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ACCPL

Financial Performance

In 2024, Accretion Pharmaceuticals's revenue was 573.76 million, an increase of 329.70% compared to the previous year's 133.53 million. Earnings were 67.94 million, an increase of 355.08%.